RxDoctor Payments DataLook up a doctor →

Gagandeep Bal

Nurse Practitioner · Ridgeland, MSNPI 1578072245

Payments from drug & device makers

$12,788in general payments, 2019–2025

Across 844 payments — averaging $15.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AbbVie$1K
  • Lilly USA, LLC$1K
  • AstraZeneca$1K
  • Axsome Therapeutics, Inc.$627
  • Amgen$592
  • plus $6K from 46 others

What the payments were for

  • Food & beverage$12,72099%
  • Education$681%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,788 in reported general payments places this provider in the 95th percentile of 1,090 nurse practitioner providers in Mississippi.

See all nurse practitioner providers in Mississippi

Medicare billing

Part B allowed, 2024
$1,401
Medicare patients
17
Services billed
30

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide72$136,824
JardianceEmpagliflozin97$85,012
TrulicityDulaglutide33$44,758
EliquisApixaban47$39,890
ProliaDenosumab22$37,606
JanuviaSitagliptin Phosphate31$37,401
Tresiba Flextouch U-200Insulin Degludec49$37,214
FarxigaDapagliflozin Propanediol27$30,200
MyrbetriqMirabegron16$12,506
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog13$10,726
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$10,414
Tresiba Flextouch U-100Insulin Degludec19$9,194
XareltoRivaroxaban13$8,358
Synjardy XrEmpagliflozin/Metformin Hcl12$6,897
Novolog FlexpenInsulin Aspart23$4,627

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,709$136,82472 claims
Boehringer IngelheimJardiance, Synjardy Xr$388$91,909109 claims
Lilly USA, LLCTrulicity$1,052$44,75833 claims
PfizerEliquis$569$39,89047 claims
AmgenProlia$592$37,60622 claims
MerckJanuvia$39$37,40131 claims
AstraZenecaFarxiga$1,027$30,20027 claims
Astellas Pharma US IncMyrbetriq$198$12,50616 claims
GSKTrelegy Ellipta$83$10,41411 claims
Johnson & JohnsonXarelto$169$8,35813 claims
AbbVieSynthroid$1,461$3,44732 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,090 nurse practitioner providers in Mississippi.

Other nurse practitioner in Ridgeland

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →